clascoterone sold brand name winlevi antiandrogen medication used topically treatment also development higher concentration treatment androgendependent scalp hair loss brand name medication used cream application skin instance face clascoterone antiandrogen antagonist androgen receptor ar biological target androgens testosterone shows minimal systemic absorption applied medication developed cassiopea intrepid approved us food drug administration fda acne august us food drug administration fda considers firstinclass clascoterone indicated topical treatment acne vulgaris people aged twelve years age two large phase iii randomized controlled trials evaluated effectiveness clascoterone treatment acne period clascoterone decreased acne symptoms defined treatment success endpoint achieved individuals clascoterone relative individuals comparative effectiveness clascoterone males females small pilot randomized controlled trial found clascoterone cream decreased acne symptoms similar significantly greater extent tretinoin active comparator used phase iii clinical trials clascoterone hence unclear clascoterone compares therapies used treatment clascoterone available form mgg cream topical effects local skin reactions clascoterone similar placebo two large phase iii randomized controlled suppression axis hpa axis may occur clascoterone therapy individuals due cortexolone hpa axis suppression measured cosyntropin stimulation test observed occur adolescents adults using clascoterone hpa axis function returned normal within weeks following discontinuation hyperkalemia elevated potassium levels occurred clascoteronetreated individuals placebotreated clascoterone steroidal antiandrogen antagonist androgen receptor ar biological target androgens testosterone dihydrotestosterone bioassay topical potency medication greater progesterone flutamide finasteride equivalent cyproterone likewise significantly efficacious antiandrogen ar antagonists enzalutamide spironolactone scalp dermal papilla cells sebocytes steadystate levels clascoterone occur within days twice daily dosage g clascoterone cream applied twice daily maximal circulating levels clascoterone ngml areaunderthecurve levels dosing interval hngml average circulating levels clascoterone rodents clascoterone found possess strong local antiandrogenic activity negligible systemic antiandrogenic activity administered via subcutaneous along lines medication progonadotropic plasma protein binding clascoterone regardless clascoterone rapidly hydrolyzed cortexolone compound possible primary metabolite clascoterone based invitro studies human liver treatment clascoterone cortexolone levels detectable generally near low limit quantification clascoterone may also produce metabolites including elimination clascoterone fully characterized clascoterone also known cortexolone well synthetic pregnane steroid derivative progesterone specifically propionate ester analogue clascoterone corticosteroids related clascoterone instance cortisone acetate prednisolone acetate show antiandrogenic activity animals similarly esters unexpectedly found possess antiandrogenic clascoterone also known cortexolone selected development based optimal drug medication approved us food drug administration fda treatment acne august fda approved clascoterone based evidence two clinical trials trial trial participants years age acne trials conducted sites united states poland romania bulgaria ukraine georgia participants applied clascoterone vehicle placebo cream twice daily neither participants health care providers knew treatment given trial benefit clascoterone comparison placebo assessed weeks treatment using investigators global assessment iga score measures severity disease scale decrease number acne clascoterone international nonproprietary name united states adopted clascoterone suggested possible treatment hidradenitis suppurativa acne inversa androgendependent skin httpsenwikipediaorgwikiclascoterone